共 50 条
- [1] REAL-WORLD ADHERENCE AND PERSISTENCE AMONG ELDERLY PATIENTS WITH T2DM INITIATING DULAGLUTIDE VS. LIRAGLUTIDE OR EXENATIDE ONCE-EEKLY IN THE US[J]. VALUE IN HEALTH, 2019, 22 : S159 - S159Yu, M.Xu, Y.Kwan, A.Bunniran, S.Mody, R.Meah, Y.Changamire, T.Nair, R.
- [2] Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (06) : 995 - 1003Mody, ReemaGrabner, MichaelYu, MariaTurner, RalphKwan, Anita Y. M.York, WhitneyLando, Laura Fernandez
- [3] Association of Treatment Persistence and Adherence With Real-World Outcomes Among Insulin-Treated Patients With Type 2 Diabetes Mellitus (T2DM)[J]. DIABETES, 2012, 61 : A4 - A4Wei, WenhuiPan, ChunshenXie, LinBaser, Onur
- [4] Remogliflozin in Indian T2DM Patients: A Real-World Study[J]. DIABETES, 2020, 69Bhattacharya, SupratikKatare, Sagar
- [5] A real-world clinical experience on effectiveness of remogliflozin etabonate in management of Indian patients with T2DM[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186Mahapatra, H.Dalai, S.Sahoo, A.Khuntia, M.
- [6] Real-World A1C Changes and Prescribing Provider Types among T2DM Patients Initiating Treatment with Oral Semaglutide[J]. DIABETES, 2022, 71Frazer, Monica S.Swift, CarolineLeszko, MichaelSargent, AndrewBuysman, ErinAlvarez, Sara B.Noone, JoshuaGuevarra, Mico
- [7] Real-World (RW) Glycemic Control and Medication Adherence among Patients with Type 2 Diabetes Mellitus (T2DM) Initiated on Canagliflozin[J]. DIABETES, 2016, 65 : A304 - A305Jain, RahulCai, JenniferFu, An-ChenChow, WingTan, Hiangkiat
- [8] ADHERENCE AND PERSISTENCE IN PATIENTS INITIATING TREATMENT WITH INJECTABLE THERAPIES FOR TYPE 2 DIABETES MELLITUS (T2DM) IN SPAIN[J]. VALUE IN HEALTH, 2015, 18 (07) : A612 - A612Sicras-Mainar, A.Navarro, R.Ruiz, L.Morano, R.
- [9] Clinical Effectiveness of Canagliflozin 100mg in T2DM Patients-A Real-World Study[J]. DIABETES, 2019, 68Chakravorty, Saibal, Sr.Patel, Vikas Kumar
- [10] REAL-WORLD ADHERENCE IN MEDICARE PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) FOR EXENATIDE QW AND LIRAGLUTIDE QD[J]. VALUE IN HEALTH, 2015, 18 (03) : A57 - A57Tarr, A.Nguyen, H.Dufour, R.Bullano, M.